Literature DB >> 29658322

Clinical effectiveness and versatility of a sealing hemostatic patch (HEMOPATCH) in multiple surgical specialties.

Kevin M Lewis1, Shelly Ikeme1, Tolu Olubunmi2, Carl Erik Kuntze1.   

Abstract

INTRODUCTION: Intraoperative surgical sealants and hemostatic agents have been shown to reduce postoperative complications, transfusions, and hospital resource utilization. Despite availability of these agents, the incidence and burden of bleeding remains high and surgeons' requirements for hemostatic control continue to evolve. A burgeoning class of hemostatic agents are hemostatic patches, which offer package-to-patient readiness and direct application. In addition, hemostatic patches may provide tissue sealing capabilities. Areas covered: This review focuses on the clinical effectiveness, versatility, and surgical efficiency of HEMOPATCH as a surgical sealant and hemostatic agent in various surgical specialties including: cardiac, digestive (hepatic, gastrointestinal, pancreatic), urological, neurological, and endocrine. Expert commentary: Among hemostatic patches, HEMOPATCH is a valuable tool to stop bleeding without adverse events across various surgical specialties. Clinical evidence demonstrates the safety, clinical effectiveness, and versatility of HEMOPATCH as a unique surgical adjunct in patients undergoing complex and routine surgical procedures. Larger randomized-controlled clinical studies, or clinical registries, will continue to be used to evaluate its performance and versatility, particularly for sealing tissues and closing the dura. In the current field of surgical sealing and hemostasis, however, HEMOPATCH represents the next step in improving patient outcomes.

Entities:  

Keywords:  EVARREST; HEMOPATCH; TACHOSIL; VERISET; hemostasis; hemostatic patch; sealing; surgery

Mesh:

Substances:

Year:  2018        PMID: 29658322     DOI: 10.1080/17434440.2018.1464909

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  7 in total

1.  PEG-coated patch parenchymal closure technique and initial outcomes during minimally invasive partial nephrectomy.

Authors:  Ryan McLarty; Benjamin Beech; Jan K Rudzinski; Blair St Martin; Howard Evans
Journal:  Can Urol Assoc J       Date:  2021-08-26       Impact factor: 1.862

2.  Nanostructured fibrin agarose hydrogel as a novel haemostatic agent.

Authors:  Rafael Campos-Cuerva; Beatriz Fernández-Muñoz; Francisco Farfán López; Sheila Pereira Arenas; Mónica Santos-González; Luis Lopez-Navas; Miguel Alaminos; Antonio Campos; Jordi Muntané; Carmen Cepeda-Franco; Miguel Ángel Gómez-Bravo
Journal:  J Tissue Eng Regen Med       Date:  2019-03-20       Impact factor: 3.963

3.  Hemopatch® as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation.

Authors:  Marie C Hupe; Maximilian Büttner; Pouriya Faraj Tabrizi; Axel S Merseburger; Markus A Kuczyk; Florian Imkamp
Journal:  Adv Ther       Date:  2020-12-04       Impact factor: 3.845

4.  Polyethylene glycol-coated collagen patch (hemopatch®) in open partial nephrectomy.

Authors:  Michael Staehler; S Rodler; M Schott; J Casuscelli; C Stief; A Spek; B Schlenker
Journal:  World J Urol       Date:  2021-09-03       Impact factor: 4.226

5.  Subtotal cholecystectomy for Mirizzi syndrome: Should we ever remove the stone? A case report.

Authors:  Michela Zanatta; Giovanna Brancato; Guido Basile; Francesco Basile; Marcello Donati
Journal:  Ann Med Surg (Lond)       Date:  2022-02-12

6.  Effectiveness of Hemopatch® versus Surgicel® Original to control mild and moderate liver bleeding.

Authors:  Selman Uranues; Abraham Fingerhut; Eve Levin; Daniel Spazierer; Nastaran Rahimi; Bernhard Baumgartner
Journal:  BMC Surg       Date:  2022-08-14       Impact factor: 2.030

7.  Hemopatch® is effective and safe to use: real-world data from a prospective European registry study.

Authors:  Carlo Lombardo; Santiago Lopez-Ben; Ugo Boggi; Piotr Gutowski; Tomas Hrbac; Lukas Krska; Javier Marquez-Rivas; Domenico Russello; Elisa York; Mario Zacharias
Journal:  Updates Surg       Date:  2022-08-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.